Is zopiclone safe for a 64‑year‑old patient with ischemic heart disease (ICD)?

Zopiclone Should Be Used With Caution in This Patient, But Is Not Absolutely Contraindicated

For a 64-year-old with ischemic heart disease, zopiclone carries meaningful cardiovascular risks that warrant careful consideration, though it may be safer than benzodiazepines if insomnia treatment is necessary.

Key Cardiovascular Concerns

The most concerning evidence comes from a 2020 study showing that benzodiazepines were associated with significantly higher rates of heart failure rehospitalization compared to Z-drugs (including zopiclone) in patients with heart failure 1. While this suggests Z-drugs may be relatively safer than benzodiazepines in cardiac patients, it does not establish absolute safety.

Additionally, a 2026 population study found that zolpidem (a related Z-drug) was independently associated with increased risk of cardiac arrhythmias, particularly paroxysmal tachycardia and atrial flutter (adjusted HR 1.983) 2. While this study examined zolpidem specifically, the pharmacological similarity to zopiclone raises concern about class effects.

Dosing Considerations for This Age Group

At 64 years old, this patient is approaching the threshold where dose reduction becomes critical:

• Standard adult dose is 7.5 mg, but patients over 65-70 require dose reduction to 3.75 mg 3
• Pharmacokinetic studies show that elderly patients (particularly those over 74) have prolonged half-life (8.1 hours vs 5.1 hours) and increased bioavailability (168% vs 77%) 3
• For this 64-year-old, starting with 3.75 mg would be prudent given proximity to elderly threshold and cardiac comorbidity

Risk-Benefit Assessment

Potential Benefits:

• Improved sleep latency and duration 4, 5
• Minimal morning psychomotor impairment with short 5-hour half-life 6
• May be safer than benzodiazepines in heart failure patients 1

Significant Risks:

• Arrhythmia risk (class effect concern from zolpidem data) 2
• General hypnotic-associated risks: falls, fractures, cognitive impairment, and increased mortality 7
• Metabolic clearance may be reduced if concurrent liver dysfunction 3

Clinical Decision Algorithm

Step 1: Assess absolute necessity

• Has cognitive-behavioral therapy for insomnia (CBT-I) been attempted?
• Is insomnia significantly impacting cardiac recovery or quality of life?

Step 2: If pharmacotherapy needed:

• Start with 3.75 mg (half the standard dose) given age proximity to elderly threshold and cardiac disease
• Avoid benzodiazepines entirely (higher cardiac risk) 1
• Use for shortest duration possible (not chronic therapy)

Step 3: Monitor for:

• New or worsening palpitations, irregular heartbeat
• Morning sedation or falls risk
• Bitter taste (common but benign side effect) 6

Step 4: Reassess within 2 weeks

• If ineffective at 3.75 mg, may cautiously increase to 7.5 mg with close cardiac monitoring
• Discontinue if any arrhythmic symptoms develop

Critical Pitfalls to Avoid

1. Do not use standard 7.5 mg dosing initially - this patient's age and cardiac status warrant conservative dosing
2. Do not prescribe for chronic use - FDA approval is for short-term use, and long-term hypnotic use is associated with dementia, fractures, and increased mortality 7
3. Do not combine with other CNS depressants - particularly avoid concurrent benzodiazepines or opioids
4. Do not ignore arrhythmia symptoms - any new palpitations or irregular heartbeat warrants immediate discontinuation 2

Bottom Line

Zopiclone is not ideal but may be acceptable for short-term use at reduced dosing (3.75 mg) if non-pharmacological approaches have failed and insomnia is significantly impacting this patient's cardiac recovery or quality of life. The evidence suggests it carries lower cardiac risk than benzodiazepines 1, but the arrhythmia signal from related Z-drugs 2 and general hypnotic-associated harms 7 mandate cautious use with close monitoring and a clear plan for discontinuation.